117 related articles for article (PubMed ID: 31859178)
21. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood.
Kraus JA; Felsberg J; Tonn JC; Reifenberger G; Pietsch T
Neuropathol Appl Neurobiol; 2002 Aug; 28(4):325-33. PubMed ID: 12175345
[TBL] [Abstract][Full Text] [Related]
22. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
23. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
24. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
25. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities.
Wood MD; Tihan T; Perry A; Chacko G; Turner C; Pu C; Payne C; Yu A; Bannykh SI; Solomon DA
Brain Pathol; 2018 Mar; 28(2):192-202. PubMed ID: 28960623
[TBL] [Abstract][Full Text] [Related]
26. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.
Cimino PJ; Bredemeyer A; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2015 Jun; 98(3):568-73. PubMed ID: 25910966
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
Ballester LY; Fuller GN; Powell SZ; Sulman EP; Patel KP; Luthra R; Routbort MJ
J Neuropathol Exp Neurol; 2017 Mar; 76(3):179-188. PubMed ID: 28395087
[TBL] [Abstract][Full Text] [Related]
28. Genomic landscape of salivary gland tumors.
Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
[TBL] [Abstract][Full Text] [Related]
29. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
Zeitlberger AM; Putora PM; Hofer S; Schucht P; Migliorini D; Hottinger AF; Roelcke U; Läubli H; Spina P; Bozinov O; Weller M; Neidert MC; Hundsberger T
J Neurooncol; 2022 Jul; 158(3):359-367. PubMed ID: 35486306
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
31. Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report.
Zhou K; Yao H; Zhang X; Liu J; Qi Z; Xie X; Xu X; Zhou Y; Yu Z; Wang Z; Che Y; Huang Y
Oncotarget; 2017 Jul; 8(30):50305-50313. PubMed ID: 28611289
[TBL] [Abstract][Full Text] [Related]
32. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.
Rao RD; Uhm JH; Krishnan S; James CD
Front Biosci; 2003 May; 8():e270-80. PubMed ID: 12700121
[TBL] [Abstract][Full Text] [Related]
33. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
34. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.
Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C
Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350
[TBL] [Abstract][Full Text] [Related]
35. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
36. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
[TBL] [Abstract][Full Text] [Related]
38. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
